EUCTR2012-005019-14-GB进行中（未招募）1 期
The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT Trial) - AKT inhibitor in breast cancer (STAKT study)
niversity of Nottingham0 个研究点目标入组 48 人开始时间: 2013年4月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Provision of written informed consent
- •WHO performance status 0-1
- •Able to swallow and retain oral medication
- •Pre-menopausal (if surgically sterile or use acceptable contraception) or post-menopausal.
- •Aged 18 years or over with histological confirmation of ER positive invasive breast carcinoma
- •Stage 1/2/3 or Stage 4 with primary tumour in the breast amenable to biopsies
- •scheduled to have chemotherapy (with or without surgery). New primary breast tumours (ipsi- or contra-lateral) despite prior endocrine treatment for an earlier primary breast tumour with at least 12 months interval between cessation of endocrine therapy and Visit 1 are eligible.
- •Tumours large enough to provide sufficient tissue to be taken by core-cut or tru-cut biopsy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •1Any prior treatment for breast cancer except new primary breast tumours despite prior endocrine treatment for an earlier primary breast tumour with at least 12 months interval between cessation of endocrine therapy and Visit 1.
- •2Known ER negative tumour.
- •3Female patients with histological confirmation of ER positive invasive breast carcinoma not scheduled to have chemotherapy (with or without surgery) based on tumour characteristics and local treatment protocols
- •4 Exposure to potent inhibitors or inducers of CYP3A4 or CYP2D6 or substrates of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St John’s Wort).
- •5Clinically significant abnormalities of glucose metabolism as defined by any of the following:
- •?Diagnosis of diabetes mellitus type I or II (irrespective of management).
- •?Glycosylated haemoglobin (HbA1C) =8.0% at screening (64 mmol/mol) (conversion equation for HbA1C [IFCC-HbA1C (mmol/mol) = [DCCT-HbA1C (%) – 2.15] x 10.929)
- •?Fasting Plasma Glucose = 7.0mmol/L (126 mg/dL) at screening. Fasting is defined as no caloric intake for at least 8 hours.
- •6Major surgery (excluding placement of vascular access) within 4 weeks before the first dose of study treatment.
- •7Spinal cord compression or brain metastases.
- •8As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
- •9Any of the following cardiac criteria:
- •?Mean resting corrected QT interval (QTc) >450 msec obtained from 3 consecutive ECGs.
- •?Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block.
- •?Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, a history of congenital long QT syndrome, family history of long QT syndrome or a history of unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval. Further Information regarding this is given in Appendix 8.
- •?Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA Grade 2.
- •?Uncontrolled hypotension – SBP <90 mmHg and/or DBP <50 mmHg.
- •10Absolute neutrophil count <1.5 x 109/L.
- •11Platelet count <100 x 109/L.
- •12Haemoglobin <9 g/dL (<5.59 mmol/L). [Note: any blood transfusion must be >14 days prior to the determination of a haemoglobin =9 g/dL (=5.59 mmol/L)].
- •13Alanine aminotransferase (ALT) >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases.
- •14Elevated Alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastasis and liver function is otherwise considered adequate in the investigator’s judgement.
- •15Total bil
研究者
相似试验
已完成
2 期
AKT Inhibitor in Oestrogen Positive Breast CancerInvasive Breast CancerNCT02077569University of Nottingham48
已完成
1 期
Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP ChemotherapyProstate CancerNCT02121639University Hospital Southampton NHS Foundation Trust160
撤回
不适用
Autonomic Phenotype Before and After Akt InhibitionDiagnosis of MelanomaNCT01593579Vanderbilt University
进行中（未招募）
1 期
Inhibition of AKT in combination with antibodies targeting the protein HER2 in patients with advanced or metastatic breast cancer and with a mutation in the gene PIK3CAPatients with PIK3CA-mutant, HER2-positive locally advanced or metastatic breast cancer, candidates to receive maintenance therapy with trastuzumab plus pertuzumab (HP) after first line treatment for metastatic disease with a taxane or vinorelbine plus HP.CTIS2023-508826-92-00Solti Group26
终止
1 期
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerEstrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu PositiveProgesterone Receptor NegativeProgesterone Receptor PositiveRecurrent Breast CarcinomaStage IV Breast CancerNCT01281163National Cancer Institute (NCI)4